It is a small molecule, specifically a quinolinium-based selective inhibitor of the NNMT enzyme
If a drug product is not available through the ODB program it will not be covered through OHIP+
general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 24% and 1520%, respectively
The businesses then pointed to the size of the market as evidence that regulators needed to accommodate it. Whats especially problematic, according to Ginsberg, is that now that compounding may move ahead, few lay consumers will understand the legal difference between an FDA-approved drug and a substance permitted for compounding
Generally, the effects last between two to three months
Deficiency can intensify over time